Bioxydyn provides high-standard, quantitative MR imaging services to the pharmaceutical industry and for clinical/academic R&D in small or large multi-centre studies.
Bioxydyn’s imaging biomarkers are built on scientifically leading techniques and compliant study management processes. Bioxydyn gives unique insight into disease progression and drug effects, helps pharmaceutical companies make investment decisions, and assists clinicians in developing the best treatment for patients.
Bioxydyn provides high-standard, quantitative MR imaging services to the pharmaceutical industry and for clinical/academic R&D in small or large multi-centre studies.
Bioxydyn’s imaging biomarkers are built on scientifically leading techniques and compliant study management processes. Bioxydyn gives unique insight into disease progression and drug effects, helps pharmaceutical companies make investment decisions, and assists clinicians in developing the best treatment for patients.
The imaging CRO service provided by Bioxydyn focusses on quantitative biomarkers derived from magnetic resonance imaging (MRI). MRI provides powerful, safe, and non-invasive insights into disease and drug effects. Thanks to the lack of ionising radiation, MRI provides a unique opportunity to investigate multiple time-points and to explore the evolution of treatments and diseases. The excellent safety profile allows for the study of the most sensitive patient groups.
Quantitative imaging biomarkers are measurable features extracted from medical imaging data. We use imaging biomarkers to produce repeatable, validated results that provide outstanding clinical information with smaller patient populations.
Bioxydyn offers imaging biomarkers for respiratory diseases such as cystic fibrosis, asthma, pulmonary hypertension, interstitial disease and COPD. We are the world leaders in delivering oxygen-enhanced MRI (OE-MRI) for imaging lung function.
Read moreBioxydyn provides advanced functional MRI biomarkers in oncology, using techniques such as diffusion MRI and dynamic contrast-enhanced (DCE) MRI, and is the leading CRO offering tumor hypoxia imaging to inform therapy effectiveness or characterise tumour physiology.
Read moreBioxydyn has delivered multiple studies for pharmaceutical companies using quantitative imaging of inflammation in a wide range of diseases, including functional imaging of joints in rheumatoid arthritis and osteoarthritis and renal imaging in nephritis.
Read moreBioxydyn is experienced in the deployment of quantitative MRI methods for neuroscience in conditions including multiple sclerosis, neurodevelopmental conditions, dementia and neuro-oncology. Our collaboration with Queen Square Analytics enables advanced AI methods for patient stratification with a focus on multiple sclerosis and Alzheimer's disease.
Read moreBioxydyn offers MRI measurement of liver transporter fluxes using dynamic contrast-enhanced MRI (DCE-MRI), plus other imaging biomarkers, including relaxation time measurements, in the investigation of liver diseases.
Read more
Bioxydyn helps design studies and flexibly adapts its tools to the requirements of new studies and techniques.
Bioxydyn can help establish the sponsor’s choice of sites for each study and provides on-site or remote training to ensure high quality image acquisition.
Bioxydyn checks images as they arrive and feeds back to the imaging sites so that high quality acquisition and calibration is maintained.
Using VoxelFlow, a proprietary in-house analysis and study management platform, Bioxydyn produces biomarker measurements that are reliable, repeatable and auditable.
Bioxydyn returns data, processed images and, where requested, scientific interpretation according to customer requirements.
Bioxydyn trains and works with any imaging site defined by the customer following a simple electronic qualification process. Most globally installed MRI equipment can be set up to perform our quantitative methods, and Bioxydyn can provide quick and accurate instruction and assistance as required.
Whatever the study protocol, Bioxydyn can work with your preferred imaging sites, or suggest alternatives with known expertise in a specific imaging technique.
Founded in 2009, Bioxydyn has a strong track record in the delivery of imaging services in clinical trials.
Bioxydyn has delivered numerous studies for multiple pharma/biotech and clinical/academic clients. Bioxydyn also has a strong track record in supporting, winning and delivering grant funded studies.
